Stifel analyst Jonathan Block raised the firm’s price target on Align Technology to $285 from $250 and keeps a Buy rating on the shares. The bar for Q4 is low and, while ongoing checks are currently mixed, the firm expects some upside is still present, the analyst tells investors. The firm names Align as one of its favorite stocks within Dental.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALGN:
- Align Technology put volume heavy and directionally bearish
- Align receives FDA 510(k) clearance for Invisalign Palatal Expander System
- Early notable gainers among liquid option names on December 14th
- Health Canada issues updated medical device license for Align’s Palatal Expander
- Nike upgraded, Paramount downgraded: Wall Street’s top analyst calls